1,418
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Diversely substituted sulfamides for fragment-based drug discovery of carbonic anhydrase inhibitors: synthesis and inhibitory profile

, , , ORCID Icon, ORCID Icon, , , ORCID Icon & show all
Pages 857-865 | Received 21 Feb 2022, Accepted 03 Mar 2022, Published online: 16 Mar 2022

Figures & data

Figure 1. CAIs in clinical development and clinical use.

Figure 1. CAIs in clinical development and clinical use.

Figure 2. Examples of clinically used sulfamide drugs.

Figure 2. Examples of clinically used sulfamide drugs.

Scheme 1. Synthesis of unsymmetrically substituted primary sulfamides 2a–q.

Scheme 1. Synthesis of unsymmetrically substituted primary sulfamides 2a–q.

Scheme 2. Synthesis of unsymmetrically (hetero)aromatic amine-substituted sulfamides 2r–w.

Scheme 2. Synthesis of unsymmetrically (hetero)aromatic amine-substituted sulfamides 2r–w.

Table 1. Calculated physicochemical properties and hCA I, II, IX and XII inhibitory profile of compounds 2a–w.

Figure 3. Co-crystal structure of fragment sulfamide 2v with hCA II (PDB code 7QSI).

Figure 3. Co-crystal structure of fragment sulfamide 2v with hCA II (PDB code 7QSI).

Table 2. Summary of data collection and atomic model refinement statistics for hCAII.a

Supplemental material

Supplemental Material

Download PDF (2.7 MB)